Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Total Current Liabilities (2018 - 2025)

Summit Therapeutics' Total Current Liabilities history spans 8 years, with the latest figure at $64.9 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 10.03% year-over-year to $64.9 million; the TTM value through Sep 2025 reached $64.9 million, up 10.03%, while the annual FY2024 figure was $41.7 million, 104.5% up from the prior year.
  • Total Current Liabilities reached $64.9 million in Q3 2025 per SMMT's latest filing, up from $60.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $140.2 million in Q2 2024 to a low of $11.9 million in Q2 2023.
  • Average Total Current Liabilities over 5 years is $43.4 million, with a median of $25.6 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: tumbled 68.89% in 2022, then surged 1074.82% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $25.6 million in 2021, then soared by 51.36% to $38.8 million in 2022, then crashed by 47.39% to $20.4 million in 2023, then skyrocketed by 104.5% to $41.7 million in 2024, then skyrocketed by 55.59% to $64.9 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Total Current Liabilities are $64.9 million (Q3 2025), $60.3 million (Q2 2025), and $34.9 million (Q1 2025).